Homepage Top Section 1

The approval was granted based on data obtained from the pivotal Phase III ZUMA-7 study, which is said to be the largest and longest trial of a Chimeric

As per the deal, Samsung Biologics will offer end-to-end CDMO services including cell line development, clinical drug substance and drug product production services. Samsung Biologics’ development and production

The acquisition is in accordance with the development, option and stock purchase agreement (DOSPA) entered by Fortress Biotech, Caelum, Alexion and others. Biopharmaceutical company Fortress founded Caelum, which

AZD7442 is a cocktail of two long-acting antibodies — tixagevimab (AZD8895) and cilgavimab (AZD1061). The US Vanderbilt University Medical Center-discovered LAAB combination was licenced to AstraZeneca in June last year.

Being trialled in the US, this drug is yet to gain approval from the regulatory authorities. The federal government of Australia has signed an agreement with pharma firm

TRV027 is being evaluated as a potential therapy for treating acute lung injury that leads to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients suffering

A first-in class antibody, lenzilumab  binds to and neutralises granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF is a key cytokine that causes a hyperinflammatory cascade or cytokine storm associated to

The Phase 2, two-arm, randomised, double blind, placebo controlled, multicentre study will evaluate the efficacy and safety of Ampligen in 80 subjects suffering with PCCD. This trial will

This trial will evaluate the safety, tolerability and immunogenicity of Reliance’s vaccine against Covid-19 infection in healthy subjects. The trial will also analyse the maximum tolerated dose of